Abstract. Because both raloxifene (RLX) and alfacalcidol (ALF) have been established as therapeutic agents for osteoporosis, it is tempting to speculate that the combination therapy of RLX and ALF might provide benefits over that of either one alone. However, the efficacy of the combination therapy has not been reported yet. The purpose of this study was thus to assess the efficacy of the combination therapy on bone mineral density (BMD) and bone turnover in patients with postmenopausal osteoporosis. Sixty postmenopausal patients (mean age 71.62 ± 9.9 years) with untreated osteoporosis were selected for this study, and were randomly divided into two groups by therapeutic regimen. Group A consisted of 28 patients treated with RLX plus ALF, while Group B consisted of 32 patients with RLX alone. Among them, 20 in group A and 22 in group B completed this study. Contrary to our expectations, at either 6 months or 12 months after the initiation of treatment, RLX plus ALF did not increase BMD at any of the skeletal sites measured, including lumbar spine, femur, and radius, nor did it reduce bone-specific alkaline phosphatase or N-terminal telopeptide of type I collagen more than RLX alone. Our results do not support the hypothesis that the combination therapy of RLX and ALF exerts more beneficial effects on bone compared than with RLX alone. However, it still remains unclear from this study whether the combination therapy of RLX and ALF is more efficacious in preventing fractures compared with RLX alone. Further studies are needed to clarify these issues.
IT has been well established that raloxifene (RLX) improves accelerated bone turnover, increases bone mineral density (BMD) at the lumbar spine (LS) and at the femoral neck (FN), and reduces the risk of new vertebral fractures [1] [2] [3] [4] . However, most of the previous clinical trials have failed to show its effects on the prevention of hip fractures [1, 5, 6] , although hip fractures can have devastating effects on the patient in terms of pain, disability and medical costs, and are already emerging as public health problems, as is the case with vertebral fractures [7] . Indeed, the multiple outcomes of RLX evaluation (MORE) study [1] , the largest double-blind placebo-controlled such study to date, demonstrated significant reduction of hip fractures after treatment with RLX in those with high risk of fractures, but not in the patient population as a whole [6] . On the other hand, bisphosphonates have been repeatedly reported to significantly reduce the risk of hip fractures [8] . In this regard, the effects of RLX on osteoporotic fractures seem to be somewhat insufficient.
Active vitamin D 3 analogues, including 1,25(OH) 2 D 3 and 1α(OH)D 3 (alfacalcidol [ALF] ), have been used as therapeutic agents for osteoporosis for more than two decades primarily in Japan and European countries [9] . In several clinical studies, active vitamin D 3 analogues have been shown to reduce accelerated bone turnover [9] , to maintain or increase BMD [10] [11] [12] , and to prevent osteoporotic fractures including both vertebral [10] and hip ones [13, 14] even when used alone. However, most of these studies featured a small number of patients or were of short duration, hence the effectiveness of ALF reported in them was relatively low. Thus, some investigators have argued that ALF still remains as a supplementary step to other forms of treatment of osteoporosis [15] . In general, it is tempting to consider the possibility that combination therapies might provide benefits over what could be expected from either one alone. Actually, some therapeutic agents for osteoporosis have been shown to exert more beneficial effects on BMD or bone turnover when used in combination with ALF [16] [17] [18] . However, the efficacy of the combination therapy of RLX and ALF has not been reported yet, despite the possible weakness of RLX as mentioned above.
The aim of our study was thus to examine and assess the effects of the combination therapy of RLX and ALF on BMD at several sites and bone turnover in patients with postmenopausal osteoporosis, both at diagnosis and prospectively after 6 and 12 months of treatment.
Subjects and Methods

Subjects
Sixty Japanese postmenopausal women (mean age 71.62 ± 9.9 years, from 52 to 91 years) with untreated osteoporosis, with their last menstrual period at least 2 years before, and without clinically significant postmenopausal symptoms such as hot flushing, at the beginning of this study, who initially attended the clinic of Rakuwakai Otowa Hospital between April 2004 and December 2005, were selected for this study. The diagnosis of osteoporosis was established on the basis of T-score of BMD at the LS (L2-L4) at least 2.5 SDs below the young adult mean, and along with the criteria for the diagnosis of osteoporosis in Japan of the time [19] . This study involved a one-year (at baseline, and 6 months and 12 months after the diagnosis) longitudinal examination of these 60 patients, who were divided into two groups randomly by self-drawing one sealed opaque envelope among two hundred envelopes prepared beforehand, a half of which each included a card indicating the therapeutic regimen, treatment with RLX alone, and the other half of which each included a card indicating combined therapy with RLX and ALF. Group A consisted of 28 patients treated with RLX (60 mg/day) and ALF (1.0 µg/day). Group B consisted of 32 patients treated with RLX (60 mg/day) only.
All subjects completed a questionnaire administered by the doctor or nurse prior to entry into the study, and underwent laboratory blood and urinary tests. We excluded subjects who had a history of deep venous thrombosis or other diseases (type 1 diabetes mellitus, liver disease, renal dysfunction, malignancy, hyperthyroidism, hyperparathyroidism, hypercorticoidism, or hypogonadism), those taking medications that could influence bone metabolism, such as bisphosphonates, calcitriol, calcitonin, estrogens, testosterones, steroids, thyroid hormones, diuretics, heparin or anticonvulsants, and those with lipid-lowering medications, such as statins, fibrates, and eicosapentaenoic acid. But, if they had been administered for more than 6 months at study entry, antihypertensive or glucose-lowering medications were allowed despite their possible effects upon lipid metabolism, provided that their doses were not changed throughout this study. We also excluded those who could not walk well for themselves. All the subjects underwent plain X-ray (antero-posterior and lateral views) of the LS, and those found to have scoliosis, compression fractures of all the lumbar vertebrae among L2-L4, or ectopic calcifications that could interfere with the bone mineral results were excluded. None of the subjects were smokers or drug abusers.
This study was performed in accordance with the recommendations of the Declaration of Helsinki and approved by the Ethical Committee of Rakuwakai Otowa Hospital, and all participants provided informed consent.
BMD measurements
BMD was measured at 7 sites, including LS (L2-L4), FN, trochanter, total neck, Ward's triangle, ultra distal radius (UD), distal 1/3 radius, by means of dual energy X-ray absorptiometry (DXA) (Hologic QDR 4500c; Hologic Inc., Waltham, MA, USA) at baseline, and 6 months and 12 months after the diagnosis. To eliminate technical discrepancies, the same operator measured all the subjects. The reproducibility was calculated as coefficient of variation obtained by daily measurements of a standard phantom over a 5-year period. The CV of our instrument is 0.34% with the standard phantom. Values of BMD at the LS were expressed as the mean of those at the L2-L4. T-scores and Z-scores were calculated on the basis of the normal reference values of the age-and gender-matched Japanese group provided by the DXA system manufacturer.
Biochemical measurements
All subjects underwent laboratory blood tests at baseline, at 6 months, and at 12 months. Serum samples were obtained before 8:00 AM after an overnight fast, and were immediately processed and kept frozen at -20°C until the assays were carried out. Serum total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL-C), calcium (Ca), phosphate 
Statistical analysis
Differences between two groups were analyzed with unpaired t test, and longitudinal differences in the same group with paired t-test. Statistics were calculated with StatView version 5.0 (Abacus Concepts Inc., Berkeley, CA, USA). A P value <0.05 was considered statistically significant.
Results
During the course, 8 patients in group A and 10 patients in group B discontinued this study. Among them, one patient in group A reported increased blood pressure, one in group B reported muscle pain for the entire body, and one in group A and one in group B reported leg cramps. All of these adverse events were resolved spontaneously with cessation of RLX. Other four patients (1 in group A and 3 in group B) discontinued due to relocation. The other 10 patients (5 for both groups) discontinued because they did not adhere to the protocol of this study during the course. As a result, 42 patients (20 in group A and 22 in group B) (mean age 71.07 ± 9.9 years) completed this study. Among them, calcium antagonists were used in 2 and 3 patients in group A and group B, respectively, and angiotensin II receptor antagonists were used in 2 patients in both groups. Sulfonylureas were used in one patient in both groups, and alfa-glucosidase inhibitors were used in 2 patients and one patient in group A and group B, respectively. None of the patients of this study received angiotensin converting enzyme inhibitors or insulin sensitizing agents such as thiazolidinediones. No case of venous thromboembolic event, clinical bone fracture, or other serious treatment-emergent events was reported. Table 1 shows a comparison for the baseline values between the two subgroups of the patients (group A and group B). There were no significant differences between the two subgroups in any clinical parameters assessed at baseline, including age, years since menopause, height, weight, BMI, Ca, P, TC, TG, HDL-C, LDL-C, BAP and NTx. Table 1 also shows the longitudinal characteristics of the patients in group A and group B at the time of diagnosis and at 6 months and 12 months after the baseline. There were no significant differences between the two subgroups in any clinical parameters assessed at either 6 months or 12 months, as well as at the baseline. However, compared with at baseline, some parameters showed significant change. Ca significantly decreased at 12 months in group A, and at 6 months in group B, compared with that at baseline. P significantly decreased at both 6 and 12 months in group B, compared with that at baseline. In both group A and group B, TC significantly decreased at both 6 and 12 months, and LDL-C significantly decreased at 6 months, compared with the corresponding values at baseline. In group A, BAP significantly de-creased at both 6 months and 12 months compared with that at baseline, while BAP significantly decreased at 12 months, but not at 6 months, in group B. On the other hand, NTx significantly decreased at both 6 months and 12 months in both group A and group B, compared with that at baseline. However, neither BAP nor NTx dropped below the lower limit of the reference value in Japanese premenopausal women (9.6 U/L, and 7.5 nmolBCE/L, respectively) at either 6 months or 12 months in either group A or group B. Table 2 shows a comparison for the baseline values of BMD, T score, and Z score between the two subgroups of the patients (group A and group B). BMD, T score, and Z score at all sites measured were not different at the baseline between group A and group B. Table 2 also shows the longitudinal changes of BMD, T score, and Z score of the patients. BMD, T score, and Z score at LS significantly increased at 12 months in group A (p = 0.011 for BMD and T score, and p = 0.013 for Z score), and at both 6 months and 12 months in group B (p = 0.019 for BMD and T score, and p = 0.020 for Z score, and p<0.001 for BMD, T score, and Z score, respectively), compared with those at baseline. In addition, in group B, Z-score at trochanter, and BMD and T-score at Ward's triangle significantly increased at 12 months and 6 months, respectively (p = 0.038, p = 0.021, and p = 0.021, respectively), compared with the corresponding value at baseline. In group A, on the other hand, BMD, T-score, and Z-score at UD significantly decreased unexpectedly (p = 0.043, p = 0.043, and p = 0.028, respectively), compared with those at baseline. However, there were no significant differences between the two subgroups in BMD, Tscore, and Z-score at any skeletal sites measured at either 6 months or 12 months. Likewise, the percentage values of the increase of BMD from the initial values were not different between the two subgroups at either 6 months or 12 months, except that at UD at 12 months (p = 0.012), as shown in Table 3 . Table 3 also shows the percentage values of the decrease of BAP and NTx from the initial values. Those of both BAP and NTx were statistically significant at both 6 and 12 months in both group A and group B, except for BAP at 6 months in group B. However, neither those of BAP nor NTx was significantly different between group A and group B at 6 months or 12 months.
Discussion
To the best of our knowledge, this is the first clinical study evaluating the effects of the combination therapy of RLX and ALF. In this one-year prospective study, we could not find that RLX plus ALF increased BMD more than RLX alone, at any skeletal sites measured. Consistent with our results, Higashi et al. [20] have re- . Therefore, RLX has been considered to exert its beneficial effects on bone not by increasing BMD, but rather mainly by improving 'bone quality' [21, 22] , indicating bone turnover markers, not BMD, as one of the best ways to estimate the therapeutic effects of RLX on bone at a clinical level [22] . However, in the present study, we could not find that RLX plus ALF reduced the accelerated bone turnover markers more than RLX alone. Although some investigators reported that ALF maintained or even stimulated bone formation [23] , we could not find more increase in BAP in the combination therapy compared with that in RLX alone, either. Thus, contrary to our expectations from the previous studies showing more beneficial effects of combination therapies including those of bisphosphonate plus ALF [16] and those of menatetrenone and ALF [17, 18] , our results do not support the hypothesis that the combination therapy of RLX and ALF exerts more beneficial effects on bone compared with RLX alone. Unexpectedly, BMD at the UD significantly de- Data represent mean ± SD. BMD, bone mineral density. P-values for comparisons of the parameters from the baseline: *P<0.05, **P<0.01. None of the intergroup differences reached statistical significance.
creased after combined treatment with RLX and ALF in our study. Indeed, this finding may suggest potentially deleterious effects of the combined treatment on bone. However, as Adami and Kanis [24] described in their review of the literature, in longitudinal observations using antiresorptive agents, increases in the crosssectional area may actually be associated with decreases in BMD even if bone mass is not reduced at all, because the unchanged bone mass is divided by a larger diameter to calculate BMD. More recently, Gatti et al. [25] have shown the decreased BMD at the radius with increased diameter can be associated with remarkable increases in bone strength. Thus, it remains unclear from our study how the decreased BMD at the UD after the combined treatment in our study is of clinical relevance. Further investigations are needed to elucidate this issue. Because RLX, one of the most potential selective estrogen receptor modulators, has estrogen-agonistic effects on bone, RLX is considered to exhibit bone sparing effects similar to those of hormone replacement therapy (HRT) [1] . Some investigators have already examined the combination therapy of estrogens for HRT and ALF. Gorai et al. [26] found a synergistic effect of HRT and ALF on early postmenopausal bone loss to be only marginal. In addition, neither Gallagher et al. [27] nor Komulainen et al. [28] could find any further beneficial effects on bone loss in the combination therapy of HRT and ALF compared with those in HRT alone. These results are in agreement with ours, which may suggest the possibility that the additive effect of ALF might be obscured in the conditions when bone resorption is moderately suppressed by treatment with HRT or RLX as Mizunuma et al. [29] stated in their report. Furthermore, in the MORE study, Antoniucci et al. [30] have recently revealed that vitamin D status in patients with postmenopausal osteoporosis does not affect BMD response to treatment with RLX, consistent with our results. However, on the other hand, more benefits in the combination therapy of bisphosphonates plus ALF compared with bisphosphonate alone have actually been reported in the literature [16] . Bisphosphonates strongly suppress bone resorption to reduce serum calcium levels following secondary hyperparathyroidism, which can in turn diminish their own effects [29] . Therefore, it is tempting to speculate that, when used in combination with bisphosphonates or when bone resorption is strongly suppressed, ALF can enhance the effect of bisphosphonates by correcting the negative calcium balance induced by treatment with bisphosphonates, as Ito et al. [16] suggested in their report. However, further studies are needed to clarify these issues.
Since the present study has some limitations, our results should be interpreted cautiously. First, it did not include large numbers of patients. Second, we had no control subjects or those with ALF alone to compare and be more certain of the changes found in this study. Third, whether our short-term results will similarly be found in a long-term study remains unclear. Finally, although our study could not find more benefits of the combination therapy on BMD or bone turnover markers, it did not calculate fracture risk as odds ratio. Some clinical studies have reported that changes in BMD may explain only a small portion of fracture risk reduction [31] . Others for RLX could not find significant correlation between changes in BAP or NTx and fracture risk reduction [22] . Thus, it still remains unclear whether RLX plus ALF can reduce the risk of fractures more efficaciously compared with RLX alone. In addition, although possible benefits for BMD or bone turnover have been shown in some combination therapies [16] [17] [18] 32] , the data about the efficacy of preventing fractures have not been established yet in any combination therapies, thus far [32] . Further studies in longer observation and larger number of patients are, therefore, warranted to clarify whether the combination therapy of RLX and ALF are clinically more effective in preventing fractures compared with RLX alone.
On the other hand, RLX significantly reduced TC and LDL-C in both group A and group B in this study, as has repeatedly been reported in the literature [2, 4] . In addition, the percentage decreases of TC and LDL-C were not different between the two subgroups (data not shown). Although beneficial effects of ALF on lipid metabolism were shown in some previous studies [33] , our findings suggest that treatment with ALF has no additional effect upon lipid metabolism beyond that of treatment with RLX.
Fortunately, although some patients discontinued this study due to poor adherence to the protocol, both RLX and ALF were generally well tolerated by our patients, except for some minor febrile reactions that probably had no association with treatment with RLX and/or ALF. Our finding that the rates of adverse events and withdrawal from this study were comparable for patients with or without ALF indicates the adequate safety and tolerability of the combination therapy of RLX and ALF for patients with postmenopausal osteoporosis.
To summarize, in this one-year prospective study, we could not find that RLX plus ALF increased BMD more than RLX alone, at any skeletal sites measured, and that RLX plus ALF reduced BAP nor NTx more than RLX alone. Our results do not support the hypothesis that the combination therapy of RLX and ALF exerts any more beneficial effect on bone compared with RLX alone. However, it still remains unclear from this study whether the combination therapy of RLX and ALF is clinically more effective in preventing fractures compared with RLX alone. Further studies are needed to clarify these issues.
